Restricted accessResearch articleFirst published online 2017-06
Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro
Clinical efficacy of antisense oligonucleotides (AONs) for the treatment of neuromuscular disorders depends on efficient cellular uptake and proper intracellular routing to the target. Selection of AONs with highest in vitro efficiencies is usually based on chemical or physical methods for forced cellular delivery. Since these methods largely bypass existing natural mechanisms for membrane passage and intracellular trafficking, spontaneous uptake and distribution of AONs in cells are still poorly understood. Here, we report on the unassisted uptake of naked AONs, so-called gymnosis, in muscle cells in culture. We found that gymnosis works similarly well for proliferating myoblasts as for terminally differentiated myotubes. Cell biological analyses combined with microscopy imaging showed that a phosphorothioate backbone promotes efficient gymnosis, that uptake is clathrin mediated and mainly results in endosomal-lysosomal accumulation. Nuclear localization occurred at a low level, but the gymnotically delivered AONs effectively modulated the expression of their nuclear RNA targets. Chloroquine treatment after gymnotic delivery helped increase nuclear AON levels. In sum, we demonstrate that gymnosis is feasible in proliferating and non-proliferating muscle cells and we confirm the relevance of AON chemistry for uptake and intracellular trafficking with this method, which provides a useful means for bio-activity screening of AONs in vitro.
Get full access to this article
View all access options for this article.
References
1.
BennettCF and SwayzeEE. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol, 50:259–293.
2.
PorenskyPN and BurghesAH. (2013). Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum Gene Ther, 24:489–498.
3.
ClaytonNP, NelsonCA, WeedenT, TaylorKM, MorelandRJ, ScheuleRK, PhillipsL, LegerAJ, ChengSH and Wentworth.BM (2014). Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of pompe disease. Mol Ther Nucleic Acids, 3:e206.
4.
KollbergG and HolmeE. (2009). Antisense oligonucleotide therapeutics for iron-sulphur cluster deficiency myopathy. Neuromuscul Disord, 19:833–836.
5.
van DeutekomJC, JansonAA, GinjaarIB, FrankhuizenWS, Aartsma-RusA, Bremmer-BoutM, den DunnenJT, KoopK, van der KooiAJ, et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med, 357:2677–2686.
6.
WheelerTM, LegerAJ, PandeySK, MacLeodAR, NakamoriM, ChengSH, WentworthBM, BennettCF and ThorntonCA. (2012). Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature, 488:111–115.
7.
Gonzalez-BarrigaA, MuldersSAM, van de GiessenJ, HooijerJD, BijlS, van KesselID, van BeersJ, van DeutekomJC, FransenJA, et al. (2013). Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy. Mol Ther Nucleic Acids, 2:e81.
8.
WicklundMP. (2013). The muscular dystrophies. Continuum (Minneap Minn), 19:1535–1570.
9.
Aartsma-RusA, Van DeutekomJC, FokkemaIF, Van OmmenGJ and Den DunnenJT. (2006). Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve, 34:135–144.
10.
KharrazY, GuerraJ, PessinaP, SerranoAL and Munoz-CanovesP. (2014). Understanding the process of fibrosis in Duchenne muscular dystrophy. Biomed Res Int, 2014:965631.
GroenenP and WieringaB. (1998). Expanding complexity in myotonic dystrophy. BioEssays, 20:901–912.
13.
UddB and KraheR. (2012). The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol, 11:891–905.
14.
WheelerTM, SobczakK, LueckJD, OsborneRJ, LinX, DirksenRT and ThorntonCA. (2009). Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science, 325:336–339.
15.
MuldersSA, van den BroekWJAA, WheelerTM, CroesHJE, van Kuik-RomeijnP, de KimpeSJ, FurlingD, PlatenburgGJ, GourdonG, et al. (2009). Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A, 106:13915–13920.
16.
LeeJE, BennettCF and CooperTA. (2012). RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci U S A, 109:4221–4226.
17.
LegerAJ, MosqueaLM, ClaytonNP, WuIH, WeedenT, NelsonCA, PhillipsL, RobertsE, PiepenhagenPA, et al. (2013). Systemic delivery of a peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy. Nucleic Acid Ther, 23:109–117.
18.
PandeySK, WheelerTM, JusticeSL, KimA, YounisH, GattisD, JauvinD, PuymiratJ, SwayzeEE, et al. (2015). Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J Pharmacol Exp Ther, 355:329–340.
19.
SteinCA, HansenJB, LaiJ, WuS, VoskresenskiyA, HogA, WormJ, HedtjarnM, SouleimanianN, et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res, 38:e3.
20.
SchmajukG, SierakowskaH and KoleR. (1999). Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J Biol Chem, 274:21783–21789.
21.
SazaniP, KangSH, MaierMA, WeiC, DillmanJ, SummertonJ, ManoharanM and KoleR. (2001). Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res, 29:3965–3974.
22.
JulianoRL, MingX, CarverK and LaingB. (2014). Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther, 24:101–113.
23.
JulianoRL and CarverK. (2015). Cellular uptake and intracellular trafficking of oligonucleotides. Adv Drug Deliv Rev, 87:35–45.
24.
JulianoRL, MingX and NakagawaO. (2012). Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem, 23:147–157.
25.
SoiferHS, KochT, LaiJ, HansenB, HoegA, OerumH and SteinCA. (2012). Silencing of gene expression by gymnotic delivery of antisense oligonucleotides. Methods Mol Biol, 815:333–346.
26.
SouleimanianN, DeleaveyGF, SoiferH, WangS, TiemannK, DamhaMJ and Stein.CA (2012). Antisense 2′-deoxy, 2′-fluroarabino nucleic acids (2′F-ANAs) oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids. Mol Ther Nucleic Acids, 1:e43.
27.
VerhaartIE, Tanganyika-de WinterCL, KarnaoukhTG, KolfschotenIG, de KimpeSJ, van DeutekomJC and Aartsma-RusA. (2013). Dose-dependent pharmacokinetic profiles of 2′-O-methyl phosphorothioate antisense oligonucleotides in mdx mice. Nucleic Acid Ther, 23:228–237.
28.
LuQL, RabinowitzA, ChenYC, YokotaT, YinH, AlterJ, JadoonA, Bou-GhariosG and PartridgeT. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A, 102:198–203.
29.
JirkaSM, HeemskerkH, Tanganyika-de WinterCL, MuilwijkD, PangKH, de VisserPC, JansonA, KarnaoukhTG, VermueR, et al. (2014). Peptide conjugation of 2′-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice. Nucleic Acid Ther, 24:25–36.
30.
SeznecH, Lia-BaldiniAS, DurosC, FouquetC, LacroixC, Hofmann-RadvanyiH, JunienC and GourdonG. (2000). Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability. Hum Mol Genet, 9:1185–1194.
31.
ZhuCH, MoulyV, CooperRN, MamchaouiK, BigotA, ShayJW, Di SantoJP, Butler-BrowneGS and WrightWE. (2007). Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell, 6:515–523.
32.
Van AgtmaalEL, AndréLM, WillemseM, CummingSA, van KesselIDG, van den BroekWJAA, GourdonG, FurlingD, MoulyV, et al. (2017). CRISPR/Cas9-induced (CTG·CAG)n repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing. Mol Ther, 25:24–43.
33.
YeJ, CoulourisG, ZaretskayaI, CutcutacheI, RozenS and Madden.TL (2012). Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics, 13:134.
34.
OwczarzyR, TataurovAV, WuY, MantheyJA, McQuistenKA, AlmabraziHG, PedersenKF, LinY, GarretsonJ, et al. (2008). IDT SciTools: a suite for analysis and design of nucleic acid oligomers. Nucleic Acids Res, 36:W163–W169.
35.
LivakKJ and SchmittgenTD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 25:402–408.
36.
FardaeiM, RogersMT, ThorpeHM, LarkinK, HamshereMG, HarperPS and BrookJD. (2002). Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet, 11:805–814.
37.
BoussifO, Lezoualc'hF, ZantaMA, MergnyMD, SchermanD, DemeneixB and BehrJP. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A, 92:7297–7301.
38.
MichiharaA, TodaK, KuboT, FujiwaraY, AkasakiK and TsujiH. (2005). Disruptive effect of chloroquine on lysosomes in cultured rat hepatocytes. Biol Pharm Bull, 28:947–951.
39.
MaeM, El AndaloussiS, LundinP, OskolkovN, JohanssonHJ, GuterstamP and LangelU. (2009). A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release, 134:221–227.
40.
KirchhausenT, MaciaE and PelishHE. (2008). Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol, 438:77–93.
41.
GrantS. (1998). Ara-C: cellular and molecular pharmacology. Adv Cancer Res, 72:197–233.
42.
MastroyiannopoulosNP, NicolaouP, AnayasaM, UneyJB and Phylactou.LA (2012). Down-regulation of myogenin can reverse terminal muscle cell differentiation. PLoS One, 7:e29896.
43.
TomczakKK, MarinescuVD, RamoniMF, SanoudouD, MontanaroF, HanM, KunkelLM, KohaneIS and BeggsAH. (2004). Expression profiling and identification of novel genes involved in myogenic differentiation. FASEB J, 18:403–405.
44.
SterrenburgE, TurkR, t HoenPA, van DeutekomJC, BoerJM, van OmmenGJ and den DunnenJT. (2004). Large-scale gene expression analysis of human skeletal myoblast differentiation. Neuromuscul Disord, 14:507–518.
45.
LevAA, FeenerCC, KunkelLM and BrownRHJr., (1987). Expression of the Duchenne's muscular dystrophy gene in cultured muscle cells. J Biol Chem, 262:15817–15820.
46.
LinC and EngbersenJF. (2008). Effect of chemical functionalities in poly(amido amine)s for non-viral gene transfection. J Control Release, 132:267–272.
47.
AkincA, ThomasM, KlibanovAM and LangerR. (2005). Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med, 7:657–663.
48.
BennettCF, ChiangMY, ChanH, ShoemakerJE and MirabelliCK. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol, 41:1023–1033.
49.
MingX, SatoK and JulianoRL. (2011). Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. J Control Release, 153:83–92.
50.
GoemansNM, TuliniusM, van den AkkerJT, BurmBE, EkhartPF, HeuvelmansN, HollingT, JansonAA, PlatenburgGJ, et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med, 364:1513–1522.
51.
Tanganyika-de WinterCL, HeemskerkH, KarnaoukhTG, van PuttenM, de KimpeSJ, van DeutekomJ and Aartsma-RusA. (2012). Long-term exon skipping studies with 2′-O-methyl phosphorothioate antisense oligonucleotides in dystrophic mouse models. Mol Ther Nucleic Acids, 1:e44.
52.
DiasN and SteinCA. (2002). Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther, 1:347–355.
53.
AllenDG and WhiteheadNP. (2011). Duchenne muscular dystrophy—what causes the increased membrane permeability in skeletal muscle?. Int J Biochem Cell Biol, 43:290–294.
54.
StraubV, RafaelJA, ChamberlainJS and CampbellKP. (1997). Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol, 139:375–385.
55.
HeemskerkH, de WinterC, van KuikP, HeuvelmansN, SabatelliP, RimessiP, BraghettaP, van OmmenGJ, de KimpeS, et al. (2010). Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther, 18:1210–1217.
56.
Gonzalez-BarrigaA, KranzenJ, CroesHJ, BijlS, van den BroekWJ, van KesselID, van EngelenBG, van DeutekomJC, WieringaB, et al. (2015). Cell membrane integrity in myotonic dystrophy type 1: implications for therapy. PLoS One, 10:e0121556.
57.
GearyRS, NorrisD, YuR and BennettCF. (2015). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev, 87:46–51.
MuldersSA, van HorssenR, GerritsL, BenninkMB, PlukH, de Boer-van HuizenRT, CroesHJ, WijersM, van de LooFA, et al. (2011). Abnormal actomyosin assembly in proliferating and differentiating myoblasts upon expression of a cytosolic DMPK isoform. Biochim Biophys Acta, 1813:867–877.
60.
LehtoT, Castillo AlvarezA, GauckS, GaitMJ, CoursindelT, WoodMJ, LebleuB and BoisguerinP. (2014). Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res, 42:3207–3217.
61.
MingX. (2011). Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis. Expert Opin Drug Deliv, 8:435–449.
62.
ZhaoQ, MatsonS, HerreraCJ, FisherE, YuH and KriegAM. (1993). Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev, 3:53–66.
63.
KollerE, VincentTM, ChappellA, DeS, ManoharanM and BennettCF. (2011). Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res, 39:4795–4807.
64.
Wojtkowiak-SzlachcicA, TaylorK, Stepniak-KoniecznaE, SznajderLJ, MykowskaA, SrokaJ, ThorntonCA and SobczakK. (2015). Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Nucleic Acids Res, 43:3318–3331.
65.
BrownDA, KangSH, GryaznovSM, DeDionisioL, HeidenreichO, SullivanS, XuX and NerenbergMI. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem, 269:26801–26805.
66.
MislickKA and BaldeschwielerJD. (1996). Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci U S A, 93:12349–12354.
67.
LiangXH, SunH, ShenW and CrookeST. (2015). Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res, 43:2927–2945.
68.
MoultonHM and MoultonJD. (2010). Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta, 1798:2296–2303.
69.
LeonettiJP, MechtiN, DegolsG, GagnorC and LebleuB. (1991). Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci U S A, 88:2702–2706.
70.
FisherTL, TerhorstT, CaoX and WagnerRW. (1993). Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res, 21:3857–3865.
71.
LorenzP, BakerBF, BennettCF and SpectorDL. (1998). Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies. Mol Biol Cell, 9:1007–1023.
72.
DavisBM, McCurrachME, TanejaKL, SingerRH and HousmanDE. (1997). Expansion of a CUG trinucleotide repeat in the 3′ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc Natl Acad Sci U S A, 94:7388–7393.
73.
Aartsma-RusA. (2010). Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy. RNA Biol, 7:453–461.
74.
GodbeyWT, WuKK and MikosAG. (1999). Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci U S A, 96:5177–5181.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
